Jazz Pharmaceuticals (JAZZ) Accumulated Expenses (2010 - 2026)

Jazz Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 3.9% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 3.9% decrease from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 13.53% from the prior year.
• Accumulated Expenses slipped to $1.0 billion in Q1 2026 per JAZZ's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.1 billion in Q1 2025 and bottomed at $593.2 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $803.3 million (2022), against an average of $828.7 million.
• Across the five-year window, Accumulated Expenses jumped 61.67% in 2022 and slipped 3.9% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $803.3 million in 2022, then declined by 1.16% to $793.9 million in 2023, then advanced by 14.74% to $910.9 million in 2024, then grew by 13.53% to $1.0 billion in 2025, then fell by 1.14% to $1.0 billion in 2026.
• Per Business Quant, the three latest JAZZ Accumulated Expenses figures stand at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025).